Firm News: Drugs & Devices: Page 7

When physicians prescribe antibiotics to patients, they don’t expect their patients to develop a problem with their aorta. However, patients taking the fluoroquinolone class of antibiotics may do just that, based on elevated risk estimates found in two studies recently published in medical journals. W&L is now accepting clients who have suffered aortic dissection or…

On January 4, the U.S. Food and Drug Administration (FDA) strengthened requirements governing surgical mesh for the transvaginal repair of pelvic organ prolapse (POP). W&L hails this action as vital to addressing safety risks posed by transvaginal mesh devices. “Previously, transvaginal mesh products were classified as Class II moderate-risk medical devices, but the FDA has…

On November 18, 2015, U.S. District Judge Kathryn H. Vratil of Kansas appointed the first plaintiffs steering committee (PSC) in a federal multidistrict litigation (MDL) with a majority of women members. This is a significant and appropriate achievement given that women comprise a large segment of the lawyers in the United States and about 50…

Weitz & Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized…

Weitz & Luxenberg, P.C., is now accepting cases involving total hip arthroplasty patients who have been implanted with an OMNIlife science Apex K2 Modular Hip System hip implant. W&L began investigating these cases after reports of patient injuries appeared in medical journals. There was also a reported rate of revision in the Australian Orthopaedic Association…